| Williams Bros. Health Care | |
| 426 N Elm St, Henderson, Kentucky 42420 | |
| (270) 869-9197 |
| Name | Williams Bros. Health Care |
|---|---|
| Organization Name | Williams Bros Health Care Pharmacy Inc |
| Location | 426 N Elm St, Henderson, Kentucky 42420 |
| Type | DME Supplier - Oxygen Equipment & Supplies |
| Phone | (270) 869-9197 |
| Participate in Medicare | Medicare enrolled and may accept medicare assignment. Please check with the supplier if they accept medicare-approved amount before you get your prescription drugs, equipment or supplies from this supplier. |
News Archive
A British Medical Association (BMA) study is warning that combining over-the-counter pharmacy drugs with prescription medicine can be dangerous. The study authors say there is an over-use of pharmacy drugs as people try to manage their own health rather than going to a doctor.
Canada's cancer care system is not meeting the unique needs of young cancer patients. Adolescent and young adult (AYA) cancer patients and survivors often 'fall through the cracks' of a system that focuses on cancer in children or adults, but does not provide specialized care for this in-between group. To understand why and develop solutions, an international group of young survivors and cancer specialists will come together in Toronto.
Epizyme, Inc., a company leading the creation of a new class of personalized therapeutics for patients with genetically defined cancers, announced today that it has initiated a Phase 1 Study of EPZ-5676. EPZ-5676 is a novel small molecule inhibitor of DOT1L, a histone methyltransferase (HMT) that is critical to the development of a specific type of acute leukemia defined by rearrangement of the MLL gene (MLL-r leukemia).
Nektar Therapeutics reported today that partner Baxter International Inc. announced that the company has submitted a new drug application (NDA) to Japan's Ministry of Health, Labour and Welfare for the approval of BAX 855, an investigational, extended half-life recombinant factor VIII (rFVIII) treatment based on ADVATE [Antihemophilic Factor (Recombinant)] for patients over 12 years of age with hemophilia A.
In what is believed to be the most comprehensive molecular characterization to date of the most common - and often treatment-resistant - form of kidney cancer, researchers at Johns Hopkins' departments of pathology and oncology, Johns Hopkins Kimmel Cancer Center, and the Johns Hopkins University School of Medicine report evidence for at least three distinct subtypes of clear cell renal cell carcinoma (ccRCC), along with new revelations about the proteins that define them.
› Verified 4 days ago
| NPI Number | 1033559422 |
| Organization Name | BARRYS PHARMACY |
| Doing Business As | BARRYS MOBILITY |
| Type | DME Supplier - Oxygen Equipment & Supplies |
| Address | 426 7th St, Henderson, KY 42420 |
| Phone Number | 270-869-9197 |
News Archive
A British Medical Association (BMA) study is warning that combining over-the-counter pharmacy drugs with prescription medicine can be dangerous. The study authors say there is an over-use of pharmacy drugs as people try to manage their own health rather than going to a doctor.
Canada's cancer care system is not meeting the unique needs of young cancer patients. Adolescent and young adult (AYA) cancer patients and survivors often 'fall through the cracks' of a system that focuses on cancer in children or adults, but does not provide specialized care for this in-between group. To understand why and develop solutions, an international group of young survivors and cancer specialists will come together in Toronto.
Epizyme, Inc., a company leading the creation of a new class of personalized therapeutics for patients with genetically defined cancers, announced today that it has initiated a Phase 1 Study of EPZ-5676. EPZ-5676 is a novel small molecule inhibitor of DOT1L, a histone methyltransferase (HMT) that is critical to the development of a specific type of acute leukemia defined by rearrangement of the MLL gene (MLL-r leukemia).
Nektar Therapeutics reported today that partner Baxter International Inc. announced that the company has submitted a new drug application (NDA) to Japan's Ministry of Health, Labour and Welfare for the approval of BAX 855, an investigational, extended half-life recombinant factor VIII (rFVIII) treatment based on ADVATE [Antihemophilic Factor (Recombinant)] for patients over 12 years of age with hemophilia A.
In what is believed to be the most comprehensive molecular characterization to date of the most common - and often treatment-resistant - form of kidney cancer, researchers at Johns Hopkins' departments of pathology and oncology, Johns Hopkins Kimmel Cancer Center, and the Johns Hopkins University School of Medicine report evidence for at least three distinct subtypes of clear cell renal cell carcinoma (ccRCC), along with new revelations about the proteins that define them.
› Verified 4 days ago
| NPI Number | 1093020901 |
| Organization Name | BARRYS MOBILITY AND EQUIPMENT CENTER |
| Type | Durable Medical Equipment & Medical Supplies Supplier |
| Address | 426 7th St, Henderson, KY 42420 |
| Phone Number | 270-869-9197 |
News Archive
A British Medical Association (BMA) study is warning that combining over-the-counter pharmacy drugs with prescription medicine can be dangerous. The study authors say there is an over-use of pharmacy drugs as people try to manage their own health rather than going to a doctor.
Canada's cancer care system is not meeting the unique needs of young cancer patients. Adolescent and young adult (AYA) cancer patients and survivors often 'fall through the cracks' of a system that focuses on cancer in children or adults, but does not provide specialized care for this in-between group. To understand why and develop solutions, an international group of young survivors and cancer specialists will come together in Toronto.
Epizyme, Inc., a company leading the creation of a new class of personalized therapeutics for patients with genetically defined cancers, announced today that it has initiated a Phase 1 Study of EPZ-5676. EPZ-5676 is a novel small molecule inhibitor of DOT1L, a histone methyltransferase (HMT) that is critical to the development of a specific type of acute leukemia defined by rearrangement of the MLL gene (MLL-r leukemia).
Nektar Therapeutics reported today that partner Baxter International Inc. announced that the company has submitted a new drug application (NDA) to Japan's Ministry of Health, Labour and Welfare for the approval of BAX 855, an investigational, extended half-life recombinant factor VIII (rFVIII) treatment based on ADVATE [Antihemophilic Factor (Recombinant)] for patients over 12 years of age with hemophilia A.
In what is believed to be the most comprehensive molecular characterization to date of the most common - and often treatment-resistant - form of kidney cancer, researchers at Johns Hopkins' departments of pathology and oncology, Johns Hopkins Kimmel Cancer Center, and the Johns Hopkins University School of Medicine report evidence for at least three distinct subtypes of clear cell renal cell carcinoma (ccRCC), along with new revelations about the proteins that define them.
› Verified 4 days ago
| NPI Number | 1881009199 |
| Organization Name | WILLIAMS BROS. HEALTH CARE PHARMACY, INC. |
| Doing Business As | WILLIAMS BROS. HEALTH CARE |
| Type | Durable Medical Equipment & Medical Supplies Supplier |
| Address | 151 N Gardenmile Rd Ste A, Henderson, KY 42420 |
| Phone Number | 270-869-9197 |
News Archive
A British Medical Association (BMA) study is warning that combining over-the-counter pharmacy drugs with prescription medicine can be dangerous. The study authors say there is an over-use of pharmacy drugs as people try to manage their own health rather than going to a doctor.
Canada's cancer care system is not meeting the unique needs of young cancer patients. Adolescent and young adult (AYA) cancer patients and survivors often 'fall through the cracks' of a system that focuses on cancer in children or adults, but does not provide specialized care for this in-between group. To understand why and develop solutions, an international group of young survivors and cancer specialists will come together in Toronto.
Epizyme, Inc., a company leading the creation of a new class of personalized therapeutics for patients with genetically defined cancers, announced today that it has initiated a Phase 1 Study of EPZ-5676. EPZ-5676 is a novel small molecule inhibitor of DOT1L, a histone methyltransferase (HMT) that is critical to the development of a specific type of acute leukemia defined by rearrangement of the MLL gene (MLL-r leukemia).
Nektar Therapeutics reported today that partner Baxter International Inc. announced that the company has submitted a new drug application (NDA) to Japan's Ministry of Health, Labour and Welfare for the approval of BAX 855, an investigational, extended half-life recombinant factor VIII (rFVIII) treatment based on ADVATE [Antihemophilic Factor (Recombinant)] for patients over 12 years of age with hemophilia A.
In what is believed to be the most comprehensive molecular characterization to date of the most common - and often treatment-resistant - form of kidney cancer, researchers at Johns Hopkins' departments of pathology and oncology, Johns Hopkins Kimmel Cancer Center, and the Johns Hopkins University School of Medicine report evidence for at least three distinct subtypes of clear cell renal cell carcinoma (ccRCC), along with new revelations about the proteins that define them.
› Verified 4 days ago
News Archive
A British Medical Association (BMA) study is warning that combining over-the-counter pharmacy drugs with prescription medicine can be dangerous. The study authors say there is an over-use of pharmacy drugs as people try to manage their own health rather than going to a doctor.
Canada's cancer care system is not meeting the unique needs of young cancer patients. Adolescent and young adult (AYA) cancer patients and survivors often 'fall through the cracks' of a system that focuses on cancer in children or adults, but does not provide specialized care for this in-between group. To understand why and develop solutions, an international group of young survivors and cancer specialists will come together in Toronto.
Epizyme, Inc., a company leading the creation of a new class of personalized therapeutics for patients with genetically defined cancers, announced today that it has initiated a Phase 1 Study of EPZ-5676. EPZ-5676 is a novel small molecule inhibitor of DOT1L, a histone methyltransferase (HMT) that is critical to the development of a specific type of acute leukemia defined by rearrangement of the MLL gene (MLL-r leukemia).
Nektar Therapeutics reported today that partner Baxter International Inc. announced that the company has submitted a new drug application (NDA) to Japan's Ministry of Health, Labour and Welfare for the approval of BAX 855, an investigational, extended half-life recombinant factor VIII (rFVIII) treatment based on ADVATE [Antihemophilic Factor (Recombinant)] for patients over 12 years of age with hemophilia A.
In what is believed to be the most comprehensive molecular characterization to date of the most common - and often treatment-resistant - form of kidney cancer, researchers at Johns Hopkins' departments of pathology and oncology, Johns Hopkins Kimmel Cancer Center, and the Johns Hopkins University School of Medicine report evidence for at least three distinct subtypes of clear cell renal cell carcinoma (ccRCC), along with new revelations about the proteins that define them.
› Verified 4 days ago
Advanced Eyecare Associates, Llc Type: Medicare Supplier Location: 1997 Barrett Ct, Henderson, Kentucky 42420 Phone: (270) 826-9966 | |
Omnicare Of Henderson Type: Long Term Care Pharmacy Location: 1900 Us Highway 41 N, Henderson, Kentucky 42420 Phone: (270) 826-6790 | |
Crystal S Oliver Od Pllc Type: Eyewear Supplier (Equipment, not the service) Location: 1413 N Elm St, Henderson, Kentucky 42420 Phone: (270) 826-1500 | |
Deaconess Home Medical Equipment Type: Durable Medical Equipment & Medical Supplies Supplier Location: 2202 Us Hwy 41 North, Henderson, Kentucky 42420 Phone: (270) 826-4673 | |
Dunaways Imperial Pharmacy Type: Durable Medical Equipment & Medical Supplies Supplier Location: 110 3rd St, Henderson, Kentucky 42420 Phone: (270) 826-6565 |